The presence of PIK3CA mutations is associated with elevated PD-L1 expression and increased immune infiltration in CRC, while in tumors devoid of RAS mutations, these mutations correlate with poor clinical outcomes and resistance to anti-EGFR therapy [115]. This evidence concerns the gene EGFR and colorectal carcinoma.